Related Experiment Video
Updated: Aug 18, 2026
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
Proteasome inhibition in multiple myeloma: therapeutic implication
Dharminder Chauhan1, Teru Hideshima, Kenneth C Anderson
1The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract:
Normal cellular functioning requires processing of proteins regulating cell cycle, growth, and apoptosis. The ubiquitin-proteasome pathway (UBP) modulates intracellular protein degradation. Specifically, the 26S proteasome is a multienzyme protease that degrades misfolded or redundant proteins; conversely, blockade of the proteasomal degradation pathways results in accumulation of unwanted proteins and cell death. Because cancer cells are more highly proliferative than normal cells, their rate of protein translation and degradation is also higher. This notion led to the development of proteasome inhibitors as therapeutics in cancer. The FDA recently approved the first proteasome inhibitor bortezomib (Velcade), formerly known as PS-341, for the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). Ongoing studies are examining other novel proteasome inhibitors, in addition to bortezomib, for the treatment of MM and other cancers.
Insights
The ubiquitin-proteasome pathway regulates protein degradation. Inhibiting this pathway, as with bortezomib (Velcade), offers a promising therapeutic strategy for cancers like multiple myeloma.
Area of Science:
- Molecular Biology
- Biochemistry
- Oncology
Background:
- Normal cellular function relies on protein processing, including cell cycle regulation, growth, and apoptosis.
- The ubiquitin-proteasome pathway (UBP) is crucial for degrading intracellular proteins.
- Cancer cells exhibit higher proliferation rates, leading to increased protein turnover.
Purpose of the Study:
- To explore the role of the ubiquitin-proteasome pathway in cancer.
- To discuss the development and therapeutic potential of proteasome inhibitors.
- To highlight bortezomib (Velcade) as a key therapeutic agent.
Main Methods:
- Review of the ubiquitin-proteasome pathway's function in protein degradation.
- Analysis of proteasome inhibition as a cancer treatment strategy.
- Examination of clinical applications and ongoing research of proteasome inhibitors.
Main Results:
- Blockade of proteasomal degradation pathways leads to the accumulation of unwanted proteins and cell death.
- Proteasome inhibitors have been developed as therapeutics for cancer due to the higher protein turnover in cancer cells.
- Bortezomib (Velcade) is FDA-approved for multiple myeloma treatment.
Conclusions:
- Proteasome inhibitors represent a significant advancement in cancer therapy, particularly for multiple myeloma.
- Further research is investigating novel proteasome inhibitors for various cancers.
- Targeting the ubiquitin-proteasome pathway offers a viable strategy for cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Drugs that Stabilize Microtubules
01:30Inhibitors of Viral Protein Synthesis